Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B.
about
Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus.Elecsys hepatitis B surface antigen quantitative assay: performance evaluation and correlation with hepatitis B virus DNA during 96 weeks of follow-up in chronic hepatitis B patients.The role of HBsAg quantification for monitoring natural history and treatment outcome.Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility.Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analoguesHBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients.Virological and serological tools to optimize the management of patients with chronic hepatitis B.The role of interleukin-27 in predicting spontaneous HBeAg seroconversion in chronic hepatitis B infection.Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response.Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E.Loss of HBsAg and antiviral treatment: from basics to clinical significance.Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.Quantitative hepatitis B surface antigen predicts the antiviral response and hepatocellular carcinoma development in patients with chronic hepatitis B.Association of on-treatment serum hepatitis B surface antigen level with sustained virological response to nucleos(t)ide analog in patients with hepatitis B e-antigen positive chronic hepatitis B.Clinical utility of hepatitis B surface antigen kinetics in treatment-naïve chronic hepatitis B patients during long-term entecavir therapy.
P2860
Q35739079-B1AD200C-1B98-4AAA-8C91-7BC728AF4A71Q36365030-2B8ED116-FE66-414B-BB1B-45916D89E84DQ38071397-540CE8D4-BE20-45DC-AB7C-09C9085EA375Q38177851-1DD4997A-F8C3-4F7A-A93D-329047A0FAAAQ38224440-8A08FF83-979C-4FED-A40F-706C2604B8AEQ38295840-63024DBB-2DA0-431F-8DC6-0A1216DC87F9Q38685589-EDD2DF99-C4A0-4A46-A5E8-7671EEB68075Q40362295-DD3ADB69-F8BF-4C08-B552-EA5EA06A618CQ40493686-440BF247-5738-49A8-A7E2-08D67F78F441Q42199429-E13B506B-A01F-4E27-A7F9-DAE6C4408DC2Q42235230-52FA803E-C365-4BF5-96F6-6DFB6741EFAAQ42279126-A9500433-8B6F-4EBD-B9FE-4F29E0E4BE9FQ42333895-0CDF1288-FE49-4162-AD14-959B0437B07AQ45067577-FB7C966F-46AA-433A-A32A-48EE666A0B28Q49885455-C411C570-ACAB-45BE-82ED-0B71E80B056A
P2860
Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Correlation of serum hepatitis ...... ents with chronic hepatitis B.
@en
Correlation of serum hepatitis ...... ents with chronic hepatitis B.
@nl
type
label
Correlation of serum hepatitis ...... ents with chronic hepatitis B.
@en
Correlation of serum hepatitis ...... ents with chronic hepatitis B.
@nl
prefLabel
Correlation of serum hepatitis ...... ents with chronic hepatitis B.
@en
Correlation of serum hepatitis ...... ents with chronic hepatitis B.
@nl
P2093
P2860
P356
P1476
Correlation of serum hepatitis ...... ents with chronic hepatitis B.
@en
P2093
Jae Youn Cheong
Myoung Hee Lee
Soon Sun Kim
Sung Won Cho
P2860
P304
P356
10.1002/JMV.22089
P577
2011-07-01T00:00:00Z